Copyright
©The Author(s) 2023.
World J Clin Cases. Oct 16, 2023; 11(29): 6984-6994
Published online Oct 16, 2023. doi: 10.12998/wjcc.v11.i29.6984
Published online Oct 16, 2023. doi: 10.12998/wjcc.v11.i29.6984
Table 2 Patient characteristics, laboratory values, and clinical outcomes
Variables1 | Overall cases (n = 512) | Propensity-score matched cases (n = 110) | ||||
MBO group (n = 56) | CBDS group (n = 460) | P value | MBO group (n = 55) | CBDS group (n = 55) | P value | |
Age (yr) | 69 (56.8-77.8) | 66 (54-78) | 0.626 | 69 (57-80) | 69 (59-83) | 0.429 |
Male gender, n (%) | 35 (62.5) | 263 (57.2) | 0.446 | 35 (63.6) | 29 (52.7) | 0.246 |
Body temperature (°C) | 36.9 (36.6-37.7) | 37.4 (36.9-38.4) | 0.001 | 36.9 (36.6-37.8) | 37.5 (37.0-38.1) | 0.003 |
Abnormal WBC count2, n (%) | 23 (41.1) | 280 (60.9) | 0.004 | 23 (41.8) | 35 (63.6) | 0.022 |
Platelet count (/µL) | 237 (169-307.5) | 197.5 (150-249.3) | 0.011 | 238.5 (169.5-312.3) | 181.5 (142.8-238.3) | 0.002 |
PT/INR | 1.2 (1.1-1.3) | 1.1 (1.1-1.2) | 0.028 | 1.2 (1.1-1.3) | 1.2 (1.1-1.2) | 0.23 |
AST (U/L) | 109 (71-209) | 167 (91-331) | 0.014 | 109 (71-221.8) | 197 (85-453) | 0.037 |
ALT (U/L) | 103 (61-198) | 189 (102-330) | 0.001 | 104 (58.5-214.5) | 140.5 (68-378.8) | 0.18 |
ALK-P (U/L) | 357 (224-548) | 181.5 (125.3-282) | < 0.001 | 357 (220-550) | 163 (121-252.8) | < 0.001 |
Total bilirubin (mg/dL) | 8.2 (4-12.8) | 3.7 (2.4–5.9) | < 0.001 | 7.5 (3.6-12.7) | 3.4 (2.2-5.1) | < 0.001 |
Creatinine (mg/dL) | 0.8 (0.7-1.0) | 1.0 (0.7-1.3) | 0.004 | 0.8 (0.7-1.0) | 0.9 (0.7-1.4) | 0.052 |
Organ dysfunction, n (%) | ||||||
Cardiovascular | 0 (0) | 20 (4.3) | 0.15 | 0 | 2 (3.6) | 0.495 |
Neurological | 6 (10.7) | 24 (5.2) | 0.122 | 5 (9.1) | 5 (9.1) | 1 |
Respiratory | 4 (7.1) | 32 (7.0) | 1 | 4 (7.3) | 8 (14.5) | 0.221 |
Renal | 4 (7.1) | 37 (8.0) | 1 | 4 (7.3) | 2 (3.6) | 0.679 |
Hepatic | 4 (7.1) | 10 (2.2) | 0.063 | 4 (7.3) | 0 | 0.118 |
Hematological | 5 (8.9) | 27 (5.9) | 0.372 | 5 (9.1) | 7 (12.7) | 0.54 |
Severity of AC, n (%) | 0.803 | |||||
Mild | 21 (37.5) | 231 (50.2) | 0.072 | 21 (38.2) | 22 (40.0) | 0.845 |
Moderate | 16 (28.6) | 128 (27.8) | 0.907 | 16 (29.1) | 13 (23.6) | 0.516 |
Severe | 19 (33.9) | 101 (22.0) | 0.045 | 18 (32.7) | 20 (36.4) | 0.688 |
Time to ERCP (h) | ||||||
Overall cases | 92.5 (43.9-137.0) | 47.4 (26.0-82.3) | < 0.001 | 89.9 (41.6-137.0) | 71.5 (41.8–109.5) | 0.418 |
Mild AC | 89.9 (40.9-116.3) | 47.3 (28.2-84.0) | 0.026 | 89.9 (38.9-116.4) | 74.6 (39.3–114.8) | 0.923 |
Moderate AC | 113.1 (65-162.3) | 44.5 (24.2-70.4) | < 0.001 | 113.1 (51.8-163.2) | 55.1 (38.1-119.2) | 0.11 |
Severe AC | 68.8 (37.0-139.6) | 65.9 (25.2-90.7) | 0.133 | 67.4 (29.1-139.4) | 77.6 (49.5-120.7) | 0.74 |
ERCP success rate, n (%) | 53 (94.6) | 456 (99.1) | 0.031 | 53 (96.4) | 51 (92.7) | 0.679 |
- Citation: Tsou YK, Su YT, Lin CH, Liu NJ. Acute cholangitis: Does malignant biliary obstruction vs choledocholithiasis etiology change the clinical presentation and outcomes? World J Clin Cases 2023; 11(29): 6984-6994
- URL: https://www.wjgnet.com/2307-8960/full/v11/i29/6984.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i29.6984